Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Serves Up More Warnings: Avon Cited For Touting Druglike Benefits

Executive Summary

Claims cited in FDA’s warning to Avon Products Inc. include statements suggesting collagen-building and wrinkle-plumping benefits, as well as comparisons to in-clinic injections and the assertion that technology in the firm’s Anew Reversalist products can help “reactivate skin’s repair process to recreate fresh skin.” Avon has 15 days to reply.

Advertisement

Related Content

Appeals Court To Hear Suit Alleging Nivea Lotion Is Unlawfully Marketed Drug
Beiersdorf Moves To Squash Suit Alleging NIVEA Firming Lotion Is An Unapproved Drug
FDA: “Extreme” Anti-Aging Claims Led To 2012 Warning Letters
Clinique’s Scientific Language Misleads Consumers – Suit
Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012
CEO McCoy: Avon Q3 “Disappointing,” But Focus Is On Future
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry
How Not To Cross FTC: Attorneys Offer Advice For Cosmeceutical Marketers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS018326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel